Drug and Therapeutics Bulletin 2008;46:21-24; doi:10.1136/dtb.2008.03.0006
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire PubMed PubMed Citation

Risks of extended-spectrum beta-lactamases

Extended-spectrum beta-lactamases (ESBLs) are an increasingly important cause of multi-drug resistant infections throughout the world.^1,2 Bacteria carrying such enzymes have long been recognised as a cause of healthcare-associated infection.³ However, of concern, the incidence of such organisms also appears to be increasing in the community, typically as a cause of urinary tract infection.^1,4 Infections due to ESBL-producing organisms can pose a major threat to life; are often difficult and expensive to treat; and can delay discharge from hospital.^5–8 Here we discuss the bacteria that produce ESBLs and treatment of patients who are infected with such organisms.

This article has been cited by other articles:

				What role for {blacktriangledown}tigecycline in infections? DTB, August 1, 2008; 46(8): 62 - 64. [Abstract] [Full Text] [PDF]